Business Wire

Transgene and NEC Start Two Clinical Trials with TG4050, an AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers

Share

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TOKYO: 6701), a leader in IT and network technologies, today announced that the first patients have been enrolled in the first-in-human trials evaluating TG4050, a therapeutic vaccine based on the myvac™ technology and powered by NEC’s cutting-edge AI capabilities. In these Phase 1 trials, TG4050 is being administered to patients with head and neck cancer who have a high risk of relapse after surgery and patients with ovarian cancer after surgery and adjuvant therapy.
Transgene’s highly innovative myvac™ technology allows the generation of a virus-based immunotherapy within a very short time frame while encoding patient-specific mutations identified and selected by NEC’s Neoantigen Prediction System.

TG4050 has been designed to target up to 30 patient-specific neoantigens (cancer cell mutations). They are selected using NEC’s Neoantigen Prediction System, an advanced AI technology that has already been applied in the field of oncology. The prediction system is based on more than two decades of expertise in AI and has been trained on proprietary immune data, allowing it to accurately prioritize and select the most immunogenic sequences.
Transgene uses its expertise in viral vectorization via myvac™ to incorporate the selected neoantigen sequences in the genome of the Modified Vaccinia virus Ankara (MVA) viral vector. The Company has also set up a unique in-house good manufacturing practice (GMP) unit dedicated to the manufacturing of the individualized batches of TG4050 needed for the clinical development of this novel therapeutic vaccine.

“As each patient’s cancer is unique, we have developed a therapy that turns their solid tumor’s genetic signature into a powerful highly specific anticancer weapon. TG4050 is based on an MVA viral vector that has proven biological activity and has the ability to elicit an immune response against tumor antigens. Our partnership with NEC ensures that TG4050 is benefitting from its world-leading expertise in artificial intelligence and its unique algorithm that is used to select up to 30 patient-specific antigens that allow this novel vaccine to induce a strong immune response. We are convinced that TG4050, which is at the crossroad of immunotherapy and big data sciences, will herald the start of a new era in the fight against cancer,” explained Philippe Archinard, Chairman and Chief Executive Officer of Transgene .

“We are excited to enroll our first patients in these trials and see TG4050 advance to the clinic. This is another step closer towards the realization of an AI-driven individualized immunotherapy for each patient. Our unique partnership with Transgene enables us to leverage its significant clinical development know-how and proven viral vector delivery platform. We are hopeful that TG4050 will make a significant difference for patients throughout the world,” commented Osamu Fujikawa, Senior Vice President, NEC Corporation.

A Phase 1 clinical trial of TG4050 is enrolling patients with ovarian cancer after surgery and first-line chemotherapy. This multi-center, one-arm trial will recruit patients in the USA and in France. Endpoints of the trial include safety, feasibility and biological activity of the therapeutic vaccine. Dr. Matthew Block, MD, PhD, immunologist and medical oncologist at the Mayo Clinic, is conducting the trial in the USA; in France, the trial will be conducted by Dr. Martinez at Toulouse-Oncopole and by Pr. Le Tourneau at Institut Curie.

Another Phase 1 clinical trial of TG4050 is enrolling patients with newly diagnosed, locoregionally advanced, HPV negative, squamous cell carcinoma of the head and neck (SCCHN) that have received an adjuvant (first-line) therapy after surgery. This multi-center, open label, randomized two arms trial will include patients in the UK and in France. Patients will receive either TG4050 monotherapy after completion of the adjuvant therapy or in combination with the standard of care at the time of recurrence. Endpoints of the trial include safety, feasibility and biological activity of the therapeutic vaccine. In France, the trial is being conducted by Pr. Delord at Toulouse-Oncopole and by Pr. Le Tourneau at Institut Curie; in the UK, the trial is coordinated by Pr. Ottensmeier from Southampton University.

Both studies are sponsored by Transgene and are co-financed by Transgene and NEC.

About Transgene
Additional information about Transgene is available at: www.transgene.fr.

About NEC Corporation
For more information, visit NEC at www.nec.com.

Contact information

Citigate Dewe Rogerson
David Dible/Sylvie Berrebi
+ 44 (0)20 7638 9571
transgene@citigatedewerogerson.com

NEC Corporation:
Joseph Jasper
j-jasper(at)ax.jp.nec.com
+81-3-3798-6511

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

RLF-100 (aviptadil) clinical trial showed rapid recovery from respiratory failure and inhibition of coronavirus replication in human lung cells3.8.2020 20:03:00 EESTPress release

NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF, OTC:RLFTF) “Relief” today announced that RLF-100 (aviptadil) showed rapid recovery from respiratory failure in the most critically ill patients with COVID-19. At the same time, independent researchers have reported that aviptadil blocked replication of the SARS coronavirus in human lung cells and monocytes. RLF-100 has been granted Fast Track designation by FDA and is being developed as a Material Threat Medical Countermeasure in cooperation with the National Institutes of Health and other federal agencies. Further research will be conducted. The first report of rapid clinical recovery under emergency use IND was posted by doctors from Houston Methodist Hospital. The report describes a 54-year-old man who developed COVID-19 while being treated for rejection of a double lung transplant and who came off a ventilator within four days.1 Similar results were subsequently seen in more than 15 patients treated under emergency use IND

Panasonic Corporation announces verification of inhibitory effect of hydroxyl radicals contained in water (nano-sized electrostatic atomized water particle) on novel coronavirus (SARS-CoV-2)3.8.2020 18:47:00 EESTPress release

Panasonic Corporation today announced that, in collaboration with Mayo Yasugi, Associate Professor, Department of Veterinary Science, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, it has verified the inhibitory effect of the hydroxyl radicals contained in water (nano-sized electrostatic atomized water particle) on the novel coronavirus (SARS-CoV-2). Hydroxyl radicals contained in water are particulate ions containing hydroxyl radicals that are generated by applying a high voltage to moisture in the air. They are characterized by being strongly oxidative and highly reactive. Panasonic has been conducting research on this technology over the past 20 years since 1997, and has verified its effectiveness in a variety of areas, including inhibiting pathogenic microorganism (bacteria, fungi, and viruses) and allergens, breaking down PM 2.5 components that have adverse effects on the human body*1. In 2012, Panasonic conducted a virus clearance test with a thi

OpenGate Capital Strengthens Management Team with Tenured Chief Financial Officer3.8.2020 17:43:00 EESTPress release

OpenGate Capital, a global private equity firm, announced today that their senior leadership team has expanded with the addition of Heather Malloy who joined the firm today as Chief Financial Officer based in the firm’s Los Angeles office. Malloy is a tenured, private equity finance executive with an extensive background in corporate strategy, structuring, and systems. She is experienced in control buyouts, senior, junior, and mezzanine debt, structured finance, and asset-backed securities. Prior to joining OpenGate, Malloy was a management consultant at Riva Ridge Management, and she previously served as Chief Operating Officer and Chief Financial Officer at Strattam Capital for six years. In her role at OpenGate Capital, Malloy is responsible for the financial and administrative matters of OpenGate Capital, the funds under OpenGate’s management, and the financial supervision of OpenGate’s global portfolio companies. Andrew Nikou, OpenGate’s Founder and Chief Executive Officer stated,

Alpega Partners with project44 to Deliver Advanced Visibility in North America and Europe3.8.2020 17:15:00 EESTPress release

Alpega, a global provider of cloud-based transportation management systems (TMS), today announced as part of its growing value-adding partner ecosystem, it has partnered with project44, a global leader in supply chain visibility for shippers and logistics service providers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200803005311/en/ Alpega Partners with project44 to Deliver Advanced Visibility in North America and Europe (Photo: Business Wire) The partnership delivers real-time truckload tracking integration and serves Alpega customers of all industries and verticals across North America and Europe. “We are happy to join efforts with Alpega to serve our global community of customers,” said Tommy Barnes, Head of Global Network Partnerships at project44. “We want to enable supply chain professionals all over the world to make informed decisions based on high quality, real-time data, and drive more operational efficiencies

 JEOL: Release of the New Scanning Electron Microscope JSM-IT700HR3.8.2020 17:00:00 EESTPress release

JEOL Ltd. (TOKYO:6951) (President & COO Izumi Oi) announces the release of a new scanning electron microscope (SEM), the JSM-IT700HR for unprecedentedly high throughput in August 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200803005011/en/ Note: The photo of the instrument is JSM-IT700HR/LA. (Photo: Business Wire) Development background Scanning electron microscopes are used in various fields, such as nanotechnology, metals, semiconductors, ceramics, medicine, and biology. In addition, SEM applications are expanding to include quality control as well as basic research. The demands are increasing for faster data acquisition of higher-quality SEM images and for easier confirmation of compositional information. Based on our award-winning predecessor of “InTouchScope™” series SEMs, the JSM-IT700HR is equipped with our in-lens Schottky field emission electron gun (FEG). This new powerful SEM satisfies the needs for obser

Immervision Orders Investigation by Ad Hoc Research to Clearly See Smartphone Camera Performance from End Users Point of View3.8.2020 16:00:00 EESTPress release

Immervision, the Montreal-based developer and licensor of patented, wide-angle optics and imaging technology, today announced its 2020 Smartphone Camera survey results in cooperation with Ad Hoc Research. Amid confusing end-user comments on photos and videos and disagreement between phone makers on what has to be done, Immervision decided to investigate what end-user like or don’t like from their phone’s cameras. It revealed no smartphone brand, even the flagship brands, is performing well in consumers’ experience in taking photos. The survey included 1,557 consumers located in California, China and South Korea who selected pictures they preferred amongst 10 images for each of the four scenes comprising city landscape and people. Photos were taken on settings from the same angle and under the same environmental conditions. Results were based on region, age, gender. Data was collected February 20 - March 5, 2020. Ad Hoc Research said, “Our study showed that with current functionalities,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom